Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Completed

Conditions: Small Cell Lung Cancer
Liposarcoma
Melanoma
Colorectal Neoplasms
Ovarian Neoplasms

Interventions: Radiation: Ionizing radiation (IR)
Radiation: Ionizing radiation (IR) therapy

First Posted Date: 2005-08-22

Last Posted Date: 2014-07-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 149

Registration Number: NCT00132704

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma

Phase 3

Completed

Conditions: Sarcoma

First Posted Date: 2005-08-19

Last Posted Date: 2008-12-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 150

Registration Number: NCT00131898

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Pre-surgical Treatment with Bevacizumab plus Chemotherapy
Drug: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab

First Posted Date: 2005-08-16

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 71

Registration Number: NCT00130780

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma

Phase 1

Completed

Conditions: Sarcoma

First Posted Date: 2005-07-13

Last Posted Date: 2013-01-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT00119301

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

PET Scans in Patients With Locally Advanced Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Procedure: positron emission tomography
Radiation: fludeoxyglucose F 18
Radiation: iodine I 124 iododeoxyuridine

First Posted Date: 2005-05-04

Last Posted Date: 2015-12-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT00109785

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Phase 2

Recruiting

Conditions: Neuroblastoma
Pheochromocytoma

Interventions: Drug: iobenguane I 131

First Posted Date: 2005-04-06

Last Posted Date: 2024-11-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT00107289

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: human gp100 plasmid DNA vaccine
Biological: mouse gp100 plasmid DNA vaccine

First Posted Date: 2005-03-04

Last Posted Date: 2013-03-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT00104845

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer

Phase 3

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Procedure: fecal occult blood test
Procedure: screening colonoscopy
Procedure: annual screening
Procedure: standard follow-up care

First Posted Date: 2005-01-19

Last Posted Date: 2024-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4952

Registration Number: NCT00102011

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota (Data collection only), Minneapolis, Minnesota, United States
🇺🇸
Kaiser Permanente Washington Health Research Institute (Data collection only), Seattle, Washington, United States
🇺🇸
Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States

and more 1 locations

Vaccine Therapy in Treating Patients With Kidney Cancer

Phase 1

Completed

Conditions: Kidney Cancer

Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine
Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine

First Posted Date: 2004-11-15

Last Posted Date: 2018-04-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT00096629

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-11-10

Last Posted Date: 2016-01-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 74

Registration Number: NCT00096486

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy